Drugs / Cytogam

Trials 6 · a red edge is where a trial was stopped

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT07096453 Oct 2025 → Aug 2027 expected cytomegalovirus infection University of Minnesota Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT04934527 Nov 2021 → Dec 2024 cytomegalovirus infection University Hospital, Bordeaux Completed No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT00881517 Jun 2009 → Oct 2011 cytomegalovirus infection Fondazione IRCCS Policlinico San Matteo di Pavia Completed No outcome recorded
Phase 2/3 NCT00137748 Jan 2001 → Jan 2006 dysgammaglobulinemia The Cleveland Clinic Completed No outcome recorded
Phase 42 trials
Phase 4 NCT06958796 Nov 2025 → Dec 2027 expected cytomegalovirus infection, disease related to solid organ transplantation Camille N. Kotton, MD Recruiting No outcome recorded
Phase 4 NCT07009548 Jun 2025 → Dec 2027 expected cytomegalovirus infection Fernanda P Silveira, MD, MS Enrolling by invitation No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 32 trials
Phase 3 NCT01376778 Comparator Apr 2012 → Oct 2019 cytomegalovirus infection The George Washington University Biostatistics Center Completed No outcome recorded
Phase 3 NCT00275509 Background Jan 2007 → Jun 2010 chronic renal failure syndrome Johns Hopkins University Completed No outcome recorded
Phase 41 trial
Phase 4 NCT01509404 Comparator Nov 2011 → Dec 2014 cytomegalovirus infection Medical University of South Carolina Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as CytoGam CytoGam - Cytomegalovirus Immune Globulin Intravenous (CMV-IGIV), is an immunoglobulin G containing a standardized amount of antibody against CMV.” NCT07009548
3

NCT00275509

NCT07096453

NCT07009548

Known as CMV hyperimmune globulin ClinicalTrials.gov intervention name — accepted as the source's own label NCT01509404
1

NCT01376778

Known as CMVIg “100 mg/kg of Cytogam (CMVIg) (Cytogam, CSL Behring, King of Prussia, PA) was administered” NCT00275509
1

NCT00137748

Known as Cytomegalovirus Immune Globulin Intravenous (Human) ClinicalTrials.gov intervention name — accepted as the source's own label NCT06958796
Known as Cytotect ClinicalTrials.gov intervention name — accepted as the source's own label NCT00881517
1

NCT04934527

Action Activate “The anti-CMV IgGs capturing virions thus activate CD16+ LTgdVd2neg with production of IFN interferon which in turn is responsible for inhibition of CMV viral multiplication.” NCT04934527
Modality Protein / enzyme biologic “intravenous immunoglobulin infusion” NCT00275509
Route Intravenous “receive Cytotect® or placebo intravenously” NCT00881517